Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
25.48
+0.19 (+0.75%)
Official Closing Price
Updated: 7:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
99
100
Next >
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
November 04, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Tops EPS Expectations In Q3 2025 Despite Revenue Decline
↗
November 04, 2025
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.
Via
Talk Markets
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
↗
November 04, 2025
With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.
Via
The Motley Fool
Topics
Energy
Stocks
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise
↗
November 04, 2025
Via
Stocktwits
Check Out What Whales Are Doing With PFE
↗
November 03, 2025
Via
Benzinga
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit
↗
November 03, 2025
Via
Stocktwits
Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
↗
November 04, 2025
Via
Benzinga
Uber, AMD And 3 Stocks To Watch Heading Into Tuesday
↗
November 04, 2025
Stock futures trading lower, watch Uber, Upwork, AMD, Starbucks, Pfizer earnings. Starbucks forms China JV. Cramer advises against AT&T.
Via
Benzinga
Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts
↗
November 03, 2025
Michael Burry's Scion Asset Management filed an updated 13F showing a new large bearish position in Palantir and Nvidia, among others.
Via
Benzinga
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session.
↗
November 03, 2025
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market...
Via
Chartmill
Tech Titans Unite and Consumer Giants Merge: Amazon-OpenAI Partnership and Kenvue Buyout Ignite S&P 500 and Nasdaq Gains
November 03, 2025
November 3, 2025 – The U.S. stock markets are experiencing a significant surge today, with both the S&P 500 and Nasdaq Composite pushing towards new highs. This bullish sentiment is largely fueled by...
Via
MarketMinute
Topics
Artificial Intelligence
Lawsuit
Stocks
Did Novo Nordisk Just Say "Checkmate" to Pfizer?
↗
November 03, 2025
These two leading drugmakers are fighting over a promising GLP-1 candidate.
Via
The Motley Fool
Topics
Intellectual Property
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
↗
November 03, 2025
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Via
Investor's Business Daily
Topics
Economy
Lawsuit
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
↗
November 03, 2025
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.
Via
Benzinga
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle
↗
November 03, 2025
Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal.
Via
Benzinga
Topics
Lawsuit
Insights Ahead: Pfizer's Quarterly Earnings
↗
November 03, 2025
Via
Benzinga
2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon
↗
November 03, 2025
The healthcare industry is chock-full of opportunities for long-term investors.
Via
The Motley Fool
Topics
Government
World Trade
How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings
↗
November 03, 2025
Pfizer offers an annual dividend yield of 6.98%, or $1.72 a year. Here's how investors can pocket a regular $500 monthly.
Via
Benzinga
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
↗
November 03, 2025
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.
Via
Benzinga
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
November 03, 2025
From
Pfizer Inc.
Via
Business Wire
2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon
↗
November 03, 2025
These healthcare stocks are making strides in very important ways.
Via
The Motley Fool
Topics
Intellectual Property
Meet the 7% Yield Dividend Stock That Could Soar in 2026
↗
November 03, 2025
This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.
Via
The Motley Fool
Topics
Intellectual Property
World Trade
1 Incredible Reason to Buy Pfizer Stock (PFE) in November
↗
November 03, 2025
What would you say to a dividend yield of 7%?
Via
The Motley Fool
3 Stocks Under $50 We’re Skeptical Of
November 02, 2025
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...
Via
StockStory
Pfizer (PFE) Q3 Earnings: What To Expect
November 02, 2025
Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
Is It Time to Dump Your Shares of Pfizer?
↗
November 02, 2025
Pfizer stock has dropped 50% over the past three years.
Via
The Motley Fool
Topics
Intellectual Property
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
November 01, 2025
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...
Via
TokenRing AI
Topics
Animal Testing
Artificial Intelligence
Economy
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
↗
October 31, 2025
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.
Via
Investor's Business Daily
Topics
Law Enforcement
Lawsuit
US Government Shutdown Threatens Deeper Economic Drag, BMO Warns
October 31, 2025
The United States is grappling with the severe economic fallout of a prolonged government shutdown, now stretching through the entire month of October 2025. With federal operations curtailed and...
Via
MarketMinute
Topics
Economy
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.